NO325947B1 - Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom. - Google Patents

Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom. Download PDF

Info

Publication number
NO325947B1
NO325947B1 NO19994778A NO994778A NO325947B1 NO 325947 B1 NO325947 B1 NO 325947B1 NO 19994778 A NO19994778 A NO 19994778A NO 994778 A NO994778 A NO 994778A NO 325947 B1 NO325947 B1 NO 325947B1
Authority
NO
Norway
Prior art keywords
agents
mycobacterial
atypical
rifabutin
clarithromycin
Prior art date
Application number
NO19994778A
Other languages
English (en)
Norwegian (no)
Other versions
NO994778L (no
NO994778D0 (no
Inventor
Thomas Julius Borody
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of NO994778D0 publication Critical patent/NO994778D0/no
Publication of NO994778L publication Critical patent/NO994778L/no
Publication of NO325947B1 publication Critical patent/NO325947B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19994778A 1997-04-01 1999-09-30 Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom. NO325947B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Publications (3)

Publication Number Publication Date
NO994778D0 NO994778D0 (no) 1999-09-30
NO994778L NO994778L (no) 1999-11-30
NO325947B1 true NO325947B1 (no) 2008-08-25

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994778A NO325947B1 (no) 1997-04-01 1999-09-30 Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom.

Country Status (16)

Country Link
US (1) US6277836B1 (OSRAM)
EP (1) EP0971735B1 (OSRAM)
JP (3) JP2001524951A (OSRAM)
AR (1) AR012304A1 (OSRAM)
AT (1) ATE389417T1 (OSRAM)
CA (1) CA2285923C (OSRAM)
CY (1) CY1109783T1 (OSRAM)
DE (1) DE69839261T2 (OSRAM)
DK (1) DK0971735T3 (OSRAM)
ES (1) ES2303351T3 (OSRAM)
IL (1) IL132145A (OSRAM)
NO (1) NO325947B1 (OSRAM)
NZ (1) NZ500696A (OSRAM)
PT (1) PT971735E (OSRAM)
SI (1) SI0971735T1 (OSRAM)
WO (1) WO1998043667A1 (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
ATE446767T1 (de) * 1999-02-12 2009-11-15 Univ Washington Gm-csf zur behandlung von morbus crohn
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20030099715A1 (en) * 2000-03-28 2003-05-29 Schwarz Franz Xaver Granulated particles with masked taste
CA2420576C (en) * 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
AU2003298937A1 (en) * 2002-12-06 2004-06-30 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
DK1828167T3 (da) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
EP2586427A3 (en) * 2005-08-24 2013-05-29 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
EP2280713A1 (en) * 2008-05-01 2011-02-09 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2011044140A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
NZ598716A (en) 2009-10-26 2014-08-29 Borody Thomas J Novel enteric combination therapy
EP2563117B1 (en) 2010-04-26 2018-02-21 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
PL2651415T3 (pl) 2010-12-13 2021-04-19 Rite-Prep Pty Ltd. Formulacje dożołądkowe i dookrężnicze oraz sposoby ich wytwarzania i zastosowania
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
NZ704014A (en) 2012-07-27 2017-10-27 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
ES2842443T3 (es) 2016-02-26 2021-07-14 Debiopharm Int Sa Medicamento para el tratamiento de infecciones del pie diabético
IL285204B2 (en) 2019-02-14 2025-02-01 Debiopharm Int Sa Formulation of apavicin, method for its preparation
EP3982975A1 (en) 2019-06-14 2022-04-20 Debiopharm International SA Afabicin for use for treating bacterial infections involving biofilm
IL299287A (en) 2020-06-30 2023-02-01 Redhill Biopharma Ltd Fixed-dose triple antibiotic combination products, dosing regimen, methods, and kits for the treatment of pulmonary mycobacterial infections other than tuberculosis
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
WO1998043667A1 (en) 1998-10-08
EP0971735A1 (en) 2000-01-19
IL132145A (en) 2005-11-20
EP0971735B1 (en) 2008-03-19
SI0971735T1 (sl) 2008-08-31
CY1109783T1 (el) 2013-09-04
DE69839261D1 (de) 2008-04-30
US6277836B1 (en) 2001-08-21
DE69839261T2 (de) 2009-03-26
JP2008024713A (ja) 2008-02-07
IL132145A0 (en) 2001-03-19
EP0971735A4 (en) 2004-02-25
JP2001524951A (ja) 2001-12-04
AR012304A1 (es) 2000-10-18
ES2303351T3 (es) 2008-08-01
CA2285923C (en) 2013-03-12
NO994778L (no) 1999-11-30
PT971735E (pt) 2008-06-02
CA2285923A1 (en) 1998-10-08
NZ500696A (en) 2002-05-31
ATE389417T1 (de) 2008-04-15
JP2012126736A (ja) 2012-07-05
DK0971735T3 (da) 2008-07-07
NO994778D0 (no) 1999-09-30

Similar Documents

Publication Publication Date Title
NO325947B1 (no) Anvendelse av anti-atypiske mycobakterielle midler for fremstilling av et medikament for behandling av inflammatorisk tarmsykdom.
US6551632B2 (en) Methods and compositions for treating inflammatory bowel disease
Kruis et al. Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
Sakurai et al. Acute right-sided hemorrhagic colitis associated with oral administration of ampicillin
Russell et al. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice
US20200101090A1 (en) Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
CN118766933B (zh) Aldisin化合物在制备治疗炎症性肠病的药物中的应用
WO2021112615A1 (ko) 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
JP2969017B2 (ja) 感染防御剤
AU774329B2 (en) Methods and compositions for treating inflammatory bowel disease
AU750813B2 (en) Methods and compositions for treating inflammatory bowel disease
Gangarosa et al. Search for a mass chemotherapeutic drug for cholera control: A study of vibrio excretion following single and multiple dose treatment
CN115279383A (zh) 用于治疗和预防胃肠炎症的普拉梭菌菌株cncm i-4573与pentasa®的组合
Manriquez et al. Clinical trials with ampicillin in typhoid fever and paratyphoid A
CN117462551B (zh) 茚地那韦和/或其衍生物在制备抗结核药物中的应用
Hanauer et al. Safety of amiselimod in healthy subjects: results from a phase 1 randomized, double-blind, placebo-controlled study
CN119868361A (zh) 莲心碱在制备抗阿尔茨海默病药物中的应用
HK1161137A (en) Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
Dailianas et al. Efficacy of an inhibitor of leukotrienes production in patients with ulcerative colitis in remission

Legal Events

Date Code Title Description
MK1K Patent expired